Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $200000.0.

  • Tarsus Pharmaceuticals' Depreciation & Amortization (CF) changed 0.0% to $200000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $820000.0, marking a year-over-year increase of 1021.51%. This contributed to the annual value of $700000.0 for FY2024, which is 591.4% down from last year.
  • Tarsus Pharmaceuticals' Depreciation & Amortization (CF) amounted to $200000.0 in Q3 2025, which was down 0.0% from $200000.0 recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $244000.0 during Q4 2023, and its lowest value of $40000.0 during Q4 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $125000.0 (2021), whereas its average is $141421.1.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 63529.41% in 2021, then crashed by 4505.49% in 2024.
  • Over the past 5 years, Tarsus Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $40000.0 in 2021, then surged by 145.0% to $98000.0 in 2022, then surged by 148.98% to $244000.0 in 2023, then decreased by 18.03% to $200000.0 in 2024, then changed by 0.0% to $200000.0 in 2025.
  • Its last three reported values are $200000.0 in Q3 2025, $200000.0 for Q2 2025, and $220000.0 during Q1 2025.